InsightfulValue
← Home

Takeda Pharmaceutical
Takeda Pharmaceutical

Pharma / Pharmaceuticals, Healthcare


Press Releases

Date Press release
2025-04-30 08:05:00 Takeda Awards $13.8 Million To U.s. Nonprofit Partners To Promote Healthy Eating And Expand Stem Education
Cambridge, mass.--(business wire)--takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
2025-04-08 07:15:00 Bioinvent Receives Milestone Payment As Takeda Moves Mezagitamab Into Phase 3
Lund, sweden / access newswire / april 8, 2025 / bioinvent international ab (\"bioinvent\") (nasdaq stockholm:binv), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million usd milestone payment, following takeda’s (tse:4502/nyse:tak) initiation of phase 3 clinical trial of mezagitamab (tak-079), identified from bioinvent’s proprietary n-coder® antibody library. the study is evaluating this potential best-in-class anti-cd83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (itp).
2025-03-03 06:45:00 Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide In Patients With Polycythemia Vera
Newark, calif. & osaka, japan & cambridge, mass.--(business wire)--protagonist therapeutics, inc. (“protagonist”) (nasdaq:ptgx) and takeda (tse:4502/nyse:tak) today announced positive topline results for the phase 3 verify study, in which phlebotomy-dependent patients with polycythemia vera (pv) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. the study met its primary endpoint and all four key secondary endpoints. rusfertide is a first.
2025-02-24 03:01:00 The European Medicines Agency (ema) Has Approved An Additional Subcutaneous Administration Option For Takhzyro® (lanadelumab) For Patients Aged 12 Years And Above With Recurrent Attacks Of Hereditary Angioedema (hae)
Takhzyro solution for injection in 2 ml pre-filled pen is now approved to facilitate subcutaneous administration in adolescent (aged 12 years and above) and adult patients with hae.1 the pre-filled pen option is designed to allow for an individualized treatment approach for adolescent and adult hae patients. in the eu, takhzyro is approved for routine prevention of recurrent hae attacks in patients aged 2 years and older.1 zurich , feb. 24, 2025 /prnewswire/ -- takeda (tse: 4502) (nyse: tak) announced today that the ema has approved an additional 2 ml pre-filled pen option for takhzyro® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (hae).1 the additional subcutaneous administration option expands takeda’s offering in this space, showing dedication to the hae community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce hae burden and improving their quality of life.
2025-01-30 09:00:00 Suffolk Celebrates Topping Off For A Game-changing New Takeda Facility In Kendall Square Where Science, Art And Community Will Converge
Boston--(business wire)--suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 kendall. designed by cbt architects, 585 kendall is a mixed-use lab/office building and performing arts center in the canal district of kendall square. the event recognized the construction teams that played a vital role in reaching this significant milestone. takeda has leased the property’s approximately 600,000-square-foot of la.
2025-01-30 02:04:00 SnVsaWUgS2 ltIFdpbGwg U3VjY2VlZC BDaHJpc3Rv cGhlIFdlYm VyIEFzIENl byBPZiBUYW tlZGEgSW4g SnVuZSAyMD I2
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRv a3lvOjQ1MD IvbnlzZTp0 YWspIGFubm 91bmNlZCB0 b2RheSB0aG F0IGl0cyBi b2FyZCBvZi BkaXJlY3Rv cnMgbWFkZS B0aGUgZGVj aXNpb24gdW 5hbmltb3Vz bHkgdG8gYX Bwb2ludCBq dWxpZSBraW 0sIGN1cnJl bnRseSBwcm VzaWRlbnQg b2YgdGFrZW Rh4oCZcyB1 LnMuIGJ1c2 luZXNzIHVu aXQsIGFzIH RoZSBzdWNj ZXNzb3IgdG 8gY2hyaXN0 b3BoZSB3ZW JlciwgdGFr ZWRh4oCZcy BwcmVzaWRl bnQsIGNoaW VmIGV4ZWN1 dGl2ZSBvZm ZpY2VyIChj ZW8pIGFuZC ByZXByZXNl bnRhdGl2ZS BkaXJlY3Rv ciwgd2hlbi Btci4gd2Vi ZXIgcmV0aX JlcyBmcm9t IHRoZSBjb2 1wYW55IGlu IGp1bmUgMj AyNi4gbXJz LiBraW0gd2 lsbCBiZSBw cm9wb3NlZC BhcyBhIGNh bmRpZGF0ZS Bmb3IgZWxl Y3Rpb24gdG 8gdGhlIGJv YXJkIGF0IH Rha2VkYeKA mXMgYW5udW FsIGdlbmVy YWwgc2hhcm Voby4=
2025-01-30 01:35:00 VGFrZWRhIE RlbGl2ZXJz IFN0cm9uZy BUaGlyZC1x dWFydGVyIE Z5MjAyNCBS ZXN1bHRzOy BSYWlzZXMg RnVsbCBZZW FyIE91dGxv b2ssIEZvcm VjYXN0aW5n IFJldmVudW UgQW5kIENv cmUgT3Blcm F0aW5nIFBy b2ZpdCBNYX JnaW4gR3Jv d3Ro
T3Nha2EsIG phcGFuLS0o YnVzaW5lc3 Mgd2lyZSkt LXRha2VkYS AodG9reW86 NDUwMi9ueX NlOnRhaykg dG9kYXkgYW 5ub3VuY2Vk IGVhcm5pbm dzIHJlc3Vs dHMgZm9yIH RoZSB0aGly ZCBxdWFydG VyIG9mIGZp c2NhbCB5ZW FyIDIwMjQg KG5pbmUgbW 9udGhzIGVu ZGVkIGRlY2 VtYmVyIDMx LCAyMDI0KS BzaG93aW5n IGNvbnRpbn VlZCBhZHZh bmNlbWVudC BvZiBpdHMg Z3Jvd3RoIC YgbGF1bmNo IHByb2R1Y3 RzLCB3aGlj aCBkZWxpdm VyZWQgZG91 YmxlLWRpZ2 l0IGdyb3d0 aCBvZiAxNC 42JSBhdCBj ZXIuIHRoZS Bjb21wYW55 IGhhcyB1cG dyYWRlZCBp dHMgZnVsbC B5ZWFyIG91 dGxvb2sgZm 9yIGdyb3d0 aCwgcmVmbG VjdGluZyBz dHJvbmcgeW Vhci10by1k YXRlIHByb2 R1Y3QgcGVy Zm9ybWFuY2 UgYW5kIG9w ZXggZWZmaW NpZW5jaWVz LCBhcyB3ZW xsIGFzIHJl dmlzZWQgZm 9yZWlnbiBl eGNoYW5nZS Bhc3N1bXB0 aW9ucy4gdG FrZWRhIGNv bnRpbnVlcy B0byBhZHZh Lg==
2025-01-27 16:05:00 TmV1cm9jcm luZSBCaW9z Y2llbmNlcy BBbm5vdW5j ZXMgQW1lbm RtZW50IFRv IFN0cmF0ZW dpYyBDb2xs YWJvcmF0aW 9uIFdpdGgg VGFrZWRhIF RvIERldmVs b3AgQW5kIE NvbW1lcmNp YWxpemUgT3 NhdmFtcGF0 b3IgKGZvcm 1lcmx5IE5i aS0xMDY1OD Q1L3Rhay02 NTMp
LcKgwqDCoM KgwqDCoCBu ZXVyb2NyaW 5lIG9idGFp bnMgZXhjbH VzaXZlIHdv cmxkd2lkZS BkZXZlbG9w bWVudCBhbm QgY29tbWVy Y2lhbGl6YX Rpb24gcmln aHRzIGV4Y2 x1ZGluZyBq YXBhbiBhbm QgY29udmVy dHMgdG8gcm 95YWx0eS1i ZWFyaW5nIG xpY2Vuc2Ug Zm9yIG9zYX ZhbXBhdG9y IC3CoMKgwq DCoMKgwqAg dGFrZWRhIH JlYWNxdWly ZXMgcmlnaH RzIHRvIG9z YXZhbXBhdG 9yIGluIGph cGFuIHNhbi BkaWVnbyAs IGphbi4gMj csIDIwMjUg L3BybmV3c3 dpcmUvIC0t IG5ldXJvY3 JpbmUgYmlv c2NpZW5jZX MsIGluYy4g KG5hc2RhcT ogbmJpeCkg dG9kYXkgYW 5ub3VuY2Vk IGl0IGhhcy BhbWVuZGVk IGl0cyBhZ3 JlZW1lbnQg d2l0aCB0YW tlZGEgdG8g ZGV2ZWxvcC BhbmQgY29t bWVyY2lhbG l6ZSBvc2F2 YW1wYXRvci AobmJpLTEw NjU4NDUvdG FrLTY1Myku IHVuZGVyIH RoZSBhbWVu ZGVkIGFncm VlbWVudCwg bmV1cm9jcm luZSB3aWxs IG9idGFpbi BleGNsdXNp dmUgcmlnaH RzIGZvciBh bGwgaW5kaW NhdGlvbnMg dG8gZGV2ZW xvcCBhbmQg Y29tbWVyY2 lhbGl6ZSBv c2F2YW1wYX RvciwgYSBw b3RlbnRpYW wgZmlyc3Qt aW4tY2xhc3 MgYW1wYSBw b3NpdGl2ZS BhbGxvc3Rl cmljIG1vZH VsYXRvciBp biBkZXZlbG 9wbWVudCBm b3IgcGF0aW VudHMgd2l0 aCBpbmFkZX F1YXRlIHJl c3BvbnNlIH RvIHRyZWF0 bWVudCBvZi BtYWpvciBk ZXByZXNzaX ZlIGRpc29y ZGVyIChtZG QpIGluIGFs bCB0ZXJyaX RvcmllcyB3 b3JsZHdpZG UgZXhjZXB0 IGphcGFuLC B3aGVyZSB0 YWtlZGEgd2 lsbCByZWFj cXVpcmUgZX hjbHVzaXZl IHJpZ2h0cy 4=
2024-12-27 01:00:00 VGFrZWRhIE Fubm91bmNl cyBBcHByb3 ZhbCBPZiBI eXF2aWHCri AxMCUgUy5j LiAoc3ViY3 V0YW5lb3Vz KSBJbmplY3 Rpb24gU2V0 IEluIEphcG FuIEZvciBQ YXRpZW50cy BXaXRoIEFn YW1tYWdsb2 J1bGluZW1p YSBPciBIeX BvZ2FtbWFn bG9idWxpbm VtaWE=
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRz ZTo0NTAyL2 55c2U6dGFr KSB0b2RheS Bhbm5vdW5j ZWQgdGhhdC B0aGUgamFw YW5lc2UgbW luaXN0cnkg b2YgaGVhbH RoLCBsYWJv dXIgYW5kIH dlbGZhcmUg aGFzIGFwcH JvdmVkIHRo ZSB1c2Ugb2 YgaHlxdmlh wq4gW2ltbX VuZSBnbG9i dWxpbiBpbm Z1c2lvbiAx MCUgKGh1bW FuKSB3aXRo IHJlY29tYm luYW50IGh1 bWFuIGh5YW x1cm9uaWRh c2VdIGluIH BhdGllbnRz IHdpdGggYW dhbW1hZ2xv YnVsaW5lbW lhIG9yIGh5 cG9nYW1tYW dsb2J1bGlu ZW1pYTEsIG Rpc29yZGVy cyBjaGFyYW N0ZXJpemVk IGJ5IHZlcn kgbG93IG9y IGFic2VudC BsZXZlbHMg b2YgYW50aW JvZGllcyBh bmQgYW4gaW 5jcmVhc2Vk IHJpc2sgb2 Ygc2VyaW91 cyByZWN1cn JpbmcgaW5m ZWN0aW9uIG NhdXNlZCBi eSBwcmltYX J5IGltbXVu b2RlZmljaW VuY3kgKHBp ZCkgb3Igc2 Vjb25kYXJ5 IGltbXUu
2024-12-03 07:00:00 VGFrZWRhIF N0cmVuZ3Ro ZW5zIE9uY2 9sb2d5IFBp cGVsaW5lIF dpdGggRWxy aXRlcmNlcH QgVGhyb3Vn aCBMaWNlbn NpbmcgQWdy ZWVtZW50IF dpdGggS2Vy b3MgVGhlcm FwZXV0aWNz
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRz ZTo0NTAyL2 55c2U6dGFr KSB0b2RheS Bhbm5vdW5j ZWQgdGhhdC BpdCBoYXMg ZW50ZXJlZC BpbnRvIGFu IGV4Y2x1c2 l2ZSBsaWNl bnNpbmcgYW dyZWVtZW50 IHdpdGgga2 Vyb3MgdGhl cmFwZXV0aW NzLCBpbmMu IChuYXNkYX E6IGtyb3Mp IHRvIGZ1cn RoZXIgZGV2 ZWxvcCwgbW FudWZhY3R1 cmUgYW5kIG NvbW1lcmNp YWxpemUgZW xyaXRlcmNl cHQgd29ybG R3aWRlIG91 dHNpZGUgb2 YgbWFpbmxh bmQgY2hpbm EsIGhvbmcg a29uZyBhbm QgbWFjYXUu IGVscml0ZX JjZXB0IGlz IGEgbGF0ZS 1zdGFnZSBp bnZlc3RpZ2 F0aW9uYWwg YWN0aXZpbi BpbmhpYml0 b3IgZGVzaW duZWQgdG8g dHJlYXQgYW 5lbWlhIGFz c29jaWF0ZW Qgd2l0aCBj ZXJ0YWluIG hlbWF0b2xv Z2ljIGNhbm NlcnMsIGlu Y2x1ZGluZy BteWVsb2R5 c3BsYXN0aW Mgc3luZHJv bWVzIChtZH MpIGFuZCBt eWVsby4=
2024-11-20 11:30:00 QWxsb3kgVG hlcmFwZXV0 aWNzIFNpZ2 5zIENvbGxh Ym9yYXRpb2 4gQW5kIExp Y2Vuc2UgQW dyZWVtZW50 IFdpdGggVG FrZWRhIFRv IERldmVsb3 AgQ2VsbCBU aGVyYXB5IF BsYXRmb3Jt
VG9reW8gJi Bib3N0b24t LShidXNpbm VzcyB3aXJl KS0tYWxsb3 kgdGhlcmFw ZXV0aWNzIG luYy4gKOKA nGFsbG954o CdKSwgYSBi aW90ZWNobm 9sb2d5IGVj b3N5c3RlbS Bjb21wYW55 IGRlZGljYX RlZCB0byBk ZW1vY3JhdG l6aW5nIGFj Y2VzcyB0by BjdXR0aW5n IGVkZ2UgZH J1ZyBkaXNj b3ZlcnkgdG VjaG5vbG9n aWVzLCBhbm 5vdW5jZWQg dG9kYXkgYS BzdHJhdGVn aWMgY29sbG Fib3JhdGlv biBhbmQgbG ljZW5zZSBh Z3JlZW1lbn Qgd2l0aCB0 YWtlZGEgcG hhcm1hY2V1 dGljYWwgY2 9tcGFueSBs aW1pdGVkIC h0c2U6NDUw Mi9ueXNlOn RhayDigJx0 YWtlZGHigJ 0pIHRvIGRl dmVsb3AgdG FrZWRh4oCZ cyBwcm9wcm lldGFyeSBp bmR1Y2VkIH BsdXJpcG90 ZW50IHN0ZW 0gY2VsbCAo aXBzYykgZG VyaXZlZCBj YXItdCBjZW xsIHBsYXRm b3JtIChpY2 FyLXQpIGFu ZCBpcHNjLW Rlcml2ZWQg Y2FyLW5rIH BsYXRmb3Jt IChpY2FyLW 5rKS4gYWxs b3kgd2lsbC Bmb2N1cyBv biBhY2NlbG VyYXRpbmcu
2024-10-31 02:05:00 VGFrZWRhIE Fubm91bmNl cyBTdHJvbm cgRmlyc3Qg SGFsZiBGeT IwMjQgUmVz dWx0cyBBbm QgUmFpc2Vz IEZ1bGwgWW VhciBPdXRs b29r
T3Nha2EsIG phcGFuLS0o YnVzaW5lc3 Mgd2lyZSkt LXRha2VkYS AodG9reW86 NDUwMi9ueX NlOnRhaykg dG9kYXkgYW 5ub3VuY2Vk IGVhcm5pbm dzIHJlc3Vs dHMgZm9yIH RoZSBmaXJz dCBoYWxmIG 9mIGZpc2Nh bCB5ZWFyID IwMjQgKHNp eCBtb250aH MgZW5kZWQg c2VwdGVtYm VyIDMwLCAy MDI0KSwgd2 l0aCBjb250 aW51ZWQgbW 9tZW50dW0g aW4gaXRzIG dyb3d0aCAm IGxhdW5jaC Bwcm9kdWN0 cyBkcml2aW 5nIGdyb3d0 aC4gdGhlIG NvbXBhbnkg aGFzIHVwZ3 JhZGVkIGl0 cyBmdWxsIH llYXIgZm9y ZWNhc3RzIG FuZCBtYW5h Z2VtZW50IG d1aWRhbmNl IHRvIHJlZm xlY3Qgc3Ry b25nZXIgdG hhbiBhbnRp Y2lwYXRlZC BmaXJzdC1o YWxmIHBlcm Zvcm1hbmNl IChpbmNsdW RpbmcgbWls ZGVyIHRoYW 4gYW50aWNp cGF0ZWQgZ2 VuZXJpYyBl cm9zaW9uIG 9mIHZ5dmFu c2XCriBpbi B0aGUgdS5z LikgYW5kIH JldmlzZWQg Zm9yZWlnbi BleGNoYW5n ZSBhc3N1bX B0aW9ucy4g dC4=
2024-09-26 08:30:00 VGVtcHVzIE Fubm91bmNl cyBFeHBhbn Npb24gT2Yg Q29sbGFib3 JhdGlvbiBX aXRoIFRha2 VkYSBUbyBM ZXZlcmFnZS BNdWx0aW1v ZGFsIFJlYW wtd29ybGQg RGF0YXNldH MgQW5kIEJp b2xvZ2ljYW wgTW9kZWwg U3lzdGVtcy BJbiBPbmNv bG9neSBSZX NlYXJjaCBB bmQgRGV2ZW xvcG1lbnQ=
Q2hpY2Fnby 0tKGJ1c2lu ZXNzIHdpcm UpLS10ZW1w dXMgYWksIG luYy4gKG5h c2RhcTogdG VtKSwgYSB0 ZWNobm9sb2 d5IGNvbXBh bnkgbGVhZG luZyB0aGUg YWRvcHRpb2 4gb2YgYWkg dG8gYWR2YW 5jZSBwcmVj aXNpb24gbW VkaWNpbmUg YW5kIHBhdG llbnQgY2Fy ZSwgdG9kYX kgYW5ub3Vu Y2VzIGFuIG V4cGFuc2lv biB0byBpdH MgY29sbGFi b3JhdGlvbi B3aXRoIHRh a2VkYSAodH NlOjQ1MDIv bnlzZTp0YW spIHRoYXQg dGFrZXMgYS BkYXRhLWZp cnN0IGFwcH JvYWNoIHRv IHJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudCwgd2l0 aCB0aGUgYW ltIG9mIGVu aGFuY2luZy B0YWtlZGHi gJlzIG9uY2 9sb2d5IHJl c2VhcmNoIG FuZCBkZXZl bG9wbWVudC BlZmZvcnRz LiBhZnRlci BhbiBpbml0 aWFsIGNvbG xhYm9yYXRp b24gdGhhdC BsZXZlcmFn ZWQgdGVtcH Vz4oCZIGRl LWlkZW50aW ZpZWQgbXVs dGltb2RhbC BkYXRhc2V0 cywgdGhpcy BuZXcgYWdy ZWVtZW50IH dpbGwgZXhw YW5kIHVwb2 4u
2024-09-24 03:00:00 VGFrZWRhIF JlY2VpdmVz IEFwcHJvdm FsIEZvciBG cnV6YXFsYS AoZnJ1cXVp bnRpbmliKS BJbiBKYXBh biBGb3IgVG hlIFRyZWF0 bWVudCBPZi BVbnJlc2Vj dGFibGUgQW R2YW5jZWQg T3IgUmVjdX JyZW50IENv bG9yZWN0YW wgQ2FuY2Vy
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRz ZTo0NTAyL2 55c2U6dGFr KSB0b2RheS Bhbm5vdW5j ZWQgdGhhdC BpdCBoYXMg cmVjZWl2ZW QgYXBwcm92 YWwgZnJvbS B0aGUgamFw YW5lc2UgbW luaXN0cnkg b2YgaGVhbH RoLCBsYWJv dXIgYW5kIH dlbGZhcmUg dG8gbWFudW ZhY3R1cmUg YW5kIG1hcm tldCBmcnV6 YXFsYSBjYX BzdWxlcyAx bWcvNW1nIC hnZW5lcmlj IG5hbWU6IG ZydXF1aW50 aW5pYiksIG Egc2VsZWN0 aXZlIG9yYW wgaW5oaWJp dG9yIG9mIH Zhc2N1bGFy IGVuZG90aG VsaWFsIGdy b3d0aCBmYW N0b3IgcmVj ZXB0b3IgKH ZlZ2ZyKSAt MSwgLTIgYW 5kIC0zLCBm b3IgdGhlIH RyZWF0bWVu dCBvZiBhZH ZhbmNlZCBv ciByZWN1cn JlbnQgY29s b3JlY3RhbC BjYW5jZXIg KGNyYykgdG hhdCBpcyBu ZWl0aGVyIG N1cmFibGUg bm9yIHJlc2 VjdGFibGUg YW5kIHRoYX QgaGFzIHBy b2dyZXNzZW QgYWZ0ZXIg Y2hlbS4=
2024-09-18 10:00:00 VGFrZWRhIE NvbW1pdHMg T3ZlciAkMz IgTWlsbGlv biBJbiBGaX ZlIE5ldyBH bG9iYWwgQ2 9ycG9yYXRl IFNvY2lhbC BSZXNwb25z aWJpbGl0eS BQYXJ0bmVy c2hpcHMgVG 8gRnVydGhl ciBEcml2ZS BIZWFsdGgg SW1wYWN0IE luIDkzIENv dW50cmllcw ==
T3Nha2EsIG phcGFuICYg Y2FtYnJpZG dlLCBtYXNz Li0tKGJ1c2 luZXNzIHdp cmUpLS10YW tlZGEgKHRv a3lvOjQ1MD IvbnlzZTog dGFrKSB0b2 RheSBjb21t aXR0ZWQgan B5NC42IGJp bGxpb24gKG FwcHJveC4g dXNkIDMyIG 1pbGxpb24p IHRvIGZpdm UgbmV3IGds b2JhbCBjb3 Jwb3JhdGUg c29jaWFsIH Jlc3BvbnNp YmlsaXR5IC hjc3IpIHBh cnRuZXJzIG FzIHBhcnQg b2YgdGhlIG NvbXBhbnni gJlzIG9uZ2 9pbmcgY29t bWl0bWVudC B0byBpbXBy b3ZpbmcgaG VhbHRoIHN5 c3RlbXMgcm VzaWxpZW5j eSBpbiBsb3 cgYW5kIG1p ZGRsZS1pbm NvbWUgY291 bnRyaWVzIG Fyb3VuZCB0 aGUgd29ybG QuIHRoaXMg Y29tbWl0bW VudCBkZW1v bnN0cmF0ZX MgdGFrZWRh 4oCZcyBmb2 N1cyBvbiB0 YWNrbGluZy BzeXN0ZW1p YyBkaXNwYX JpdGllcyBh bmQgc3VwcG 9ydGluZyBs b2NhbCBsZW FkZXJzaGlw IGluIHN0cm VuZ3RoZW5p bmcgaGVhbH RoIGluZnJh c3RydWN0dX JlLCBlbXBv d2VyaW5nIG gu
Takeda Pharmaceutical

📰 Browse additional press releases for Takeda Pharmaceutical!

Sign up for free or log in
© 2024 - 2025 InsightfulValue.com. All rights reserved. Legal